249 related articles for article (PubMed ID: 37936713)
1. PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
Zhao R; Chen S; Cui W; Xie C; Zhang A; Yang L; Dong H
Front Immunol; 2023; 14():1232047. PubMed ID: 37936713
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Bioinformatics Analysis Reveals PTPN1 (PTP1B) Is a Promising Immunotherapy Target Associated with T Cell Function for Liver Cancer.
Zhu Y; Zu Y
J Healthc Eng; 2023; 2023():1533794. PubMed ID: 36741874
[TBL] [Abstract][Full Text] [Related]
3. KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer.
Liu S; Ye Z; Xue VW; Sun Q; Li H; Lu D
BMC Cancer; 2023 Apr; 23(1):307. PubMed ID: 37016301
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
5. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
6. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
Jin T; Li D; Yang T; Liu F; Kong J; Zhou Y
Oncol Rep; 2019 Aug; 42(2):717-725. PubMed ID: 31173266
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
8. PTPRO-related CD8
Dong H; Xie C; Yao Z; Zhao R; Lin Y; Luo Y; Chen S; Qin Y; Chen Y; Zhang H
Front Immunol; 2022; 13():947841. PubMed ID: 36003382
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
11. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
[No Abstract] [Full Text] [Related]
12. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
Ma P; Sun W
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
[TBL] [Abstract][Full Text] [Related]
13. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
[TBL] [Abstract][Full Text] [Related]
14. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
15. Predictive role of E2F6 in cancer prognosis and responses of immunotherapy.
Gong C; Tu Z; Long X; Liu X; Liu F; Liu J; Zhu X; Li J; Huang K
Int Immunopharmacol; 2024 Jan; 127():111302. PubMed ID: 38071912
[TBL] [Abstract][Full Text] [Related]
16. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
17. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
18. The value of
Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
[TBL] [Abstract][Full Text] [Related]
19. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
Wang Z; Liu H; Gong Y; Cheng Y
Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer.
Zhong H; Shi Q; Wen Q; Chen J; Li X; Ruan R; Zeng S; Dai X; Xiong J; Li L; Lei W; Deng J
Front Immunol; 2023; 14():1058627. PubMed ID: 36923407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
